Department of Surgery, University of Alabama at Birmingham, Birmingham, AL, USA.
Ann Surg Oncol. 2012 Nov;19(12):3879-87. doi: 10.1245/s10434-012-2435-y. Epub 2012 Jun 6.
Fluorescence imaging hardware (SPY) has recently been developed for intraoperative assessment of blood flow via detection of probes emitting in the near-infrared (NIR) spectrum. This study sought to determine if this imaging system was capable of detecting micrometastatic head and neck squamous cell carcinoma (HNSCC) in preclinical models.
A NIR fluorescent probe (IRDye800CW) was covalently linked to a monoclonal antibody targeting epidermal growth factor receptor (EGFR; panitumumab) or nonspecific IgG. HNSCC flank (SCC-1) and orthotopic (FADU and OSC19) xenografts were imaged 48-96 h after systemic injection of labeled panitumumab or IgG. The primary tumor and regional lymph nodes were dissected using fluorescence guidance with the SPY system and grossly assessed with a charge-coupled NIR system (Pearl). Histologic slides were also imaged with a NIR charged-coupled device (Odyssey) and fluorescence intensity was correlated with pathologic confirmation of disease.
Orthotopic tongue tumors were clearly delineated from normal tissue with tumor-to-background ratios of 2.9 (Pearl) and 2.3 (SPY). Disease detection was significantly improved with panitumumab-IRDye compared to IgG-IRDye800 (P < 0.05). Tissue biopsy samples (average size 3.7 mm) positive for fluorescence were confirmed for pathologic disease by histology and immunohistochemistry (n = 25 of 25). Biopsy samples of nonfluorescent tissue were proven to be negative for malignancy (n = 28 of 28). The SPY was able to detect regional lymph node metastasis (<1.0 mm) and microscopic areas of disease. Standard histological assessment in both frozen and paraffin-embedded histologic specimens was augmented using the Odyssey.
Panitumumab-IRDye800 may have clinical utility in detection and removal of microscopic HNSCC using existing intraoperative optical imaging hardware and may augment analysis of frozen and permanent pathology.
荧光成像硬件(SPY)最近已被开发用于通过检测发射近红外(NIR)光谱的探针来评估术中血流。本研究旨在确定该成像系统是否能够在临床前模型中检测头颈部鳞状细胞癌(HNSCC)的微转移。
将近红外荧光探针(IRDye800CW)与针对表皮生长因子受体(EGFR;帕尼单抗)或非特异性 IgG 的单克隆抗体共价连接。在全身注射标记的帕尼单抗或 IgG 后 48-96 小时,对 HNSCC 侧翼(SCC-1)和原位(FADU 和 OSC19)异种移植物进行成像。使用 SPY 系统进行荧光引导对原发性肿瘤和区域淋巴结进行解剖,并使用电荷耦合 NIR 系统(Pearl)进行大体评估。还使用近红外电荷耦合器件(Odyssey)对组织学切片进行成像,并将荧光强度与疾病的病理证实进行相关。
与 IgG-IRDye800 相比,用 panitumumab-IRDye 可更清楚地将原位舌肿瘤与正常组织区分开来,肿瘤与背景的比值为 2.9(Pearl)和 2.3(SPY)。与 IgG-IRDye800 相比,panitumumab-IRDye 显著提高了疾病检测能力(P < 0.05)。25 例荧光阳性的组织活检样本通过组织学和免疫组织化学证实存在病理学疾病(n = 25)。28 例非荧光组织活检样本均证实无恶性肿瘤(n = 28)。SPY 能够检测到区域淋巴结转移(<1.0mm)和微小疾病区域。在冷冻和石蜡包埋组织学标本中使用 Odyssey 增强了对标准组织学评估的分析。
帕尼单抗-IRDye800 可能具有临床实用性,可使用现有的术中光学成像硬件检测和清除微小的 HNSCC,并可能增强对冷冻和永久性病理学的分析。